North American Construction (NOA) Lags Q3 Earnings and Revenue Estimates

North American Construction Group (NOA) reported Q2 2026 revenue of $456.1M, up 23% YoY, driven by IMC acquisition and Australia growth. Adjusted EBITDA rose 17% to $93.5M, and adjusted EPS increased to $0.32. Full-year revenue guidance was raised to $1.6B-$1.8B. Net debt increased to $1.09B for acquisitions and growth. Management highlighted a $3.8B backlog and strategic shifts in oil sands and northern infrastructure.

North American Construction Group (NYSE:NOA) reiterated adjusted EBITDA guidance of C$380 million to C$420 million and free-cash-flow guidance of C$110 million to C$130 million, with midpoints at C$400 million and C$120 million. Q2 operating cash flow before working capital was C$78 million and free cash flow C$23 million. Net debt rose to C$1.1 billion. Australia backlog was C$3.4 billion with C$3.9 billion bid pipeline; total bid pipeline exceeded C$12 billion.

North American Construction Group Ltd. (NACG) reported Q2 2026 results for the quarter ended June 30, 2026. Combined revenue rose to C$456.1 million (+23% YoY) and adjusted EBITDA increased to C$93.5 million (+17% YoY). Free cash flow was C$23.0 million. NACG also declared a C$0.12 quarterly dividend and raised full-year 2026 combined revenue guidance, citing record Q2 performance and the April 7 IMC acquisition.

North American Construction Group Ltd. (NOA) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 News Release North American Construction Group Ltd. Announces Results for the Second Quarter Ended June 30, 2026 Raises Full Year 2026 Combined Revenue Guidance on Record Q2 Top-Line Performance ACHESON, Alberta, August 12, 2026 - North American Construction Group Lt

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.